8-K: Envista Holdings Reports Mixed Q3 2024 Results, Core Sales Decline

Envista Holdings Corporation announced its third quarter 2024 results, showing a decline in core sales and adjusted EBITDA compared to the same period last year, but with results in line with expectations.

Summary

• Envista Holdings Corporation reported third quarter 2024 sales of $601.0 million, a decrease compared to $631.3 million in the same quarter of 2023.
• Core sales declined by 5.3% year-over-year.
• Net income for the quarter was $8.2 million, or $0.05 per diluted share, down from $21.5 million, or $0.12 per diluted share, in Q3 2023.
• Adjusted net income was $21.1 million, or $0.12 per diluted share, compared to $75.5 million, or $0.43 per diluted share, in the prior year.
• Adjusted EBITDA was $54.9 million, significantly lower than the $123.5 million reported in the third quarter of 2023.
• The company continues to expect a core sales growth of -1% to -4% for the full year 2024.
• They also anticipate adjusted EBITDA margins between 10% and 12% for the full year.
• Envista expects to return to growth in the fourth quarter of 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant year-over-year declines in key financial metrics, although the company is expressing optimism about future improvements and is meeting expectations.

Positives

• The company's Q3 results were in line with expectations.
• There is early evidence that commercial and innovation investments are having a beneficial impact.
• Envista expects to return to growth in the fourth quarter of 2024.

Negatives

• Core sales declined by 5.3% year-over-year.
• Net income decreased significantly from $21.5 million to $8.2 million year-over-year.
• Adjusted net income decreased from $75.5 million to $21.1 million year-over-year.
• Adjusted EBITDA decreased from $123.5 million to $54.9 million year-over-year.

Risks

• The company faces risks related to the U.S. and global economy, including inflation and increasing interest rates.
• International economic, political, legal, compliance, and business factors could impact results.
• There are risks associated with product manufacturing, commodity costs, and supply chain disruptions.
• The company is exposed to risks related to competition and its ability to develop and market new products.
• Fluctuations in inventory of distributors and customers could affect performance.
• The company faces risks related to potential security breaches of its IT systems.
• There are risks related to litigation and other contingent liabilities.

Future Outlook

The company expects core sales growth of -1% to -4% and adjusted EBITDA margins between 10% and 12% for the full year 2024, with a return to growth expected in the fourth quarter.

Management Comments

• In Q3, Envista delivered results that were in line with expectations with early evidence that our commercial and innovation investments are having a beneficial impact.
• We're focusing our attention and resources in three particular areas: accelerating growth, leveraging EBS for sustained operational improvement, and advancing our high performing and inclusive culture.
• While we have much work ahead of us, I am encouraged by our pace of improvement.

Industry Context

The dental industry is competitive, and Envista's results reflect challenges in the current market environment. The company is focusing on internal improvements and innovation to drive future growth.

Comparison to Industry Standards

• Envista's core sales decline of 5.3% is a significant underperformance compared to some of its peers in the dental industry, such as Align Technology, which has shown growth in recent quarters, although specific comparisons are difficult without detailed competitor results for the same period.
• The adjusted EBITDA margin of 9.1% for the quarter is below the industry average for large dental product companies, which often see margins in the mid-teens or higher, for example, Dentsply Sirona has historically reported higher EBITDA margins.
• Envista's focus on operational improvements through the Envista Business System (EBS) is a common strategy in the industry, similar to Danaher's Business System (DBS), which is used by many of its former subsidiaries, but the results of this strategy are not yet fully reflected in the current financial performance.
• The company's expectation to return to growth in Q4 is a positive sign, but it will need to demonstrate significant improvement to meet industry benchmarks.

Stakeholder Impact

• Shareholders may be concerned about the decline in financial performance, but may be encouraged by the company's outlook for Q4.
• Employees may be affected by the company's restructuring efforts and focus on operational improvements.
• Customers may see changes in product offerings and services as the company focuses on innovation.
• Suppliers may be impacted by changes in the company's purchasing and manufacturing strategies.

Next Steps

• Envista will discuss its quarterly results and provide an updated outlook for 2024 during an investor conference call.
• The company will continue to focus on accelerating growth, leveraging EBS for operational improvement, and advancing its culture.

Key Dates

Keywords

dental, sales, EBITDA, net income, core sales, financial results, dental products, adjusted earnings, implants, orthodontics, digital imaging